10x Genomics and A*STAR Genome Institute of Singapore Launch TISHUMAP Study to Advance AI-Driven Drug Target Discovery
10x Genomics (Nasdaq: TXG) and A*STAR Genome Institute of Singapore have announced the TISHUMAP research collaboration to advance drug target discovery using spatial biology and AI. The study will analyze up to 2,500 FFPE clinical tissue samples from gastric, liver, and colorectal cancers using 10x Genomics' Xenium platform.
The collaboration leverages Xenium's unique capability to visualize gene activity within intact tissue samples at the cellular level, combined with AI to identify novel biomarkers and drug targets. The partnership includes development of custom gene panels and intelligent software pipelines to manage large-scale spatial biology data, aiming to accelerate the development of new diagnostics and personalized treatment approaches for cancer and inflammatory diseases.
10x Genomics (Nasdaq: TXG) e il Genome Institute of Singapore di A*STAR hanno annunciato la collaborazione di ricerca TISHUMAP per promuovere la scoperta di bersagli farmacologici utilizzando la biologia spaziale e l'IA. Lo studio analizzerà fino a 2.500 campioni clinici FFPE di tessuti provenienti da tumori gastrici, epatici e del colon-retto utilizzando la piattaforma Xenium di 10x Genomics.
La collaborazione sfrutta l'esclusiva capacità di Xenium di visualizzare l'attività genica all'interno di campioni di tessuto integri a livello cellulare, combinata con l'IA per identificare nuovi biomarcatori e bersagli farmacologici. Il partenariato prevede lo sviluppo di pannelli genici personalizzati e pipeline software intelligenti per gestire dati di biologia spaziale su larga scala, con l'obiettivo di accelerare lo sviluppo di nuovi strumenti diagnostici e approcci terapeutici personalizzati per il cancro e le malattie infiammatorie.
10x Genomics (Nasdaq: TXG) y el Instituto del Genoma de Singapur de A*STAR han anunciado la colaboración de investigación TISHUMAP para avanzar en el descubrimiento de objetivos farmacológicos mediante biología espacial e inteligencia artificial. El estudio analizará hasta 2.500 muestras clínicas FFPE de tejidos de cáncer gástrico, hepático y colorrectal utilizando la plataforma Xenium de 10x Genomics.
La colaboración aprovecha la capacidad única de Xenium para visualizar la actividad génica dentro de muestras de tejido intactas a nivel celular, combinada con IA para identificar nuevos biomarcadores y objetivos farmacológicos. La asociación incluye el desarrollo de paneles génicos personalizados y pipelines de software inteligentes para gestionar grandes volúmenes de datos de biología espacial, con el objetivo de acelerar el desarrollo de nuevos diagnósticos y tratamientos personalizados para el cáncer y enfermedades inflamatorias.
10x Genomics (나스닥: TXG)와 A*STAR 싱가포르 게놈 연구소는 공간 생물학과 인공지능(AI)을 활용한 약물 표적 발견을 진전시키기 위해 TISHUMAP 연구 협력을 발표했습니다. 이번 연구는 10x Genomics의 Xenium 플랫폼을 사용하여 위암, 간암, 대장암에서 최대 2,500개의 FFPE 임상 조직 샘플을 분석할 예정입니다.
이번 협력은 Xenium이 완전한 조직 샘플 내에서 세포 수준의 유전자 활동을 시각화하는 독특한 능력과 AI를 결합하여 새로운 바이오마커 및 약물 표적을 식별하는 데 중점을 둡니다. 또한 맞춤형 유전자 패널과 대규모 공간 생물학 데이터를 관리하기 위한 지능형 소프트웨어 파이프라인 개발도 포함되어 있어 암 및 염증성 질환에 대한 새로운 진단법과 개인 맞춤형 치료법 개발을 가속화하는 것을 목표로 합니다.
10x Genomics (Nasdaq : TXG) et le Genome Institute of Singapore d'A*STAR ont annoncé la collaboration de recherche TISHUMAP visant à faire progresser la découverte de cibles médicamenteuses grâce à la biologie spatiale et à l'IA. L'étude analysera jusqu'à 2 500 échantillons cliniques FFPE issus de cancers gastriques, hépatiques et colorectaux en utilisant la plateforme Xenium de 10x Genomics.
Cette collaboration exploite la capacité unique de Xenium à visualiser l'activité génique au sein d'échantillons de tissus intacts au niveau cellulaire, combinée à l'IA pour identifier de nouveaux biomarqueurs et cibles médicamenteuses. Le partenariat inclut le développement de panneaux géniques personnalisés et de pipelines logiciels intelligents pour gérer les données de biologie spatiale à grande échelle, dans le but d'accélérer le développement de nouveaux diagnostics et approches thérapeutiques personnalisées pour le cancer et les maladies inflammatoires.
10x Genomics (Nasdaq: TXG) und das A*STAR Genome Institute of Singapore haben die TISHUMAP-Forschungskooperation angekündigt, um die Entdeckung von Arzneimittelzielen mithilfe von spatialer Biologie und KI voranzutreiben. Die Studie wird bis zu 2.500 FFPE-Klinikgewebeproben von Magen-, Leber- und Darmkrebserkrankungen mit der Xenium-Plattform von 10x Genomics analysieren.
Die Kooperation nutzt die einzigartige Fähigkeit von Xenium, Genaktivität innerhalb intakter Gewebeproben auf zellulärer Ebene zu visualisieren, kombiniert mit KI zur Identifizierung neuer Biomarker und Arzneimittelziele. Die Partnerschaft umfasst die Entwicklung maßgeschneiderter Genpanels und intelligenter Software-Pipelines zur Verwaltung groß angelegter spatialer Biologiedaten, mit dem Ziel, die Entwicklung neuer Diagnostika und personalisierter Behandlungsansätze für Krebs und entzündliche Erkrankungen zu beschleunigen.
- Partnership with prestigious A*STAR Genome Institute of Singapore enhances research capabilities
- Large-scale study analyzing 2,500 clinical tissue samples demonstrates platform scalability
- Development of custom gene panels and software tools adds value to Xenium platform
- Potential to accelerate drug target discovery and diagnostic development
- None.
Insights
10x Genomics' Xenium platform partnership with A*STAR may accelerate cancer drug target discovery through unprecedented spatial biology insights.
This collaboration between 10x Genomics and Singapore's A*STAR Genome Institute represents a significant advancement in spatial biology applications. The TISHUMAP project will analyze up to 2,500 FFPE clinical tissue samples from gastric, liver, and colorectal cancers using 10x's Xenium platform. What makes this particularly valuable is that Xenium allows visualization of gene activity within intact tissue samples at the cellular level, preserving the critical spatial context that traditional methods lose.
The technical advantage here is substantial. By maintaining tissue integrity during analysis, researchers can observe not just what genes are expressed, but precisely where in the tissue microenvironment this expression occurs and how cells interact within their native context. This spatial information is crucial for understanding complex diseases like cancer, where cellular neighborhoods and interactions significantly influence disease progression and treatment response.
The integration of advanced AI with this spatial data represents a powerful approach to identify patterns across large datasets. The partnership includes developing custom gene panels specific to research questions and intelligent software pipelines to manage the enormous datasets generated. This combination of hardware (Xenium platform) and software (AI analysis tools) creates a comprehensive ecosystem for spatial biology research that could significantly accelerate biomarker and drug target discovery.
From a translational perspective, this work could establish foundations for new diagnostic approaches and precision medicine strategies, particularly for the Asian cancer types being studied, which often have distinct molecular profiles compared to Western populations.
Ambitious study will profile thousands of tumor samples to uncover novel biomarkers and therapeutic targets for cancer and inflammatory diseases
As part of the TISHUMAP study, A*STAR GIS and 10x Genomics will analyze up to 2,500 formalin-fixed paraffin-embedded (FFPE) clinical tissue samples, including those from gastric, liver and colorectal cancers. Unlike traditional methods that require tissues to be broken down, 10x Genomics' Xenium platform uniquely enables researchers to visualize gene activity directly within individual cells in intact tissues. This approach generates a comprehensive and precise molecular-level map, clearly illustrating how cells are positioned, interact and function within their natural biological context. When combined with advanced AI, this powerful capability allows researchers to detect critical patterns across large datasets swiftly, significantly advancing the identification of novel biomarkers and drug targets. The goal is to pave the way for the development of new diagnostics and, in the future, personalized treatment plans for patients.
"We are excited to partner with 10x Genomics on TISHUMAP, a transformative initiative in large-scale spatial omics for drug target discovery," said Dr. Shyam Prabhakar, Associate Director, Spatial and Single Cell Systems at A*STAR GIS. "TISHUMAP builds on A*STAR GIS' leading role in translational genomics in
This collaboration spans both data generation and analysis stages, including tailored gene panels designed for specific research questions and intelligent software pipelines for efficient management of large datasets. A*STAR GIS and 10x Genomics will work together to streamline lab workflows and build advanced tools that simplify how scientists prepare samples, capture images, and analyze spatial biology data. They'll also co-develop custom gene panels and smart software pipelines designed to handle the massive datasets generated by this cutting-edge research.
"With Xenium, we are uncovering how biology works at subcellular resolution, revealing the underlying mechanisms of health and disease. By delivering accessible and transformative spatial biology, Xenium empowers scientists everywhere to ask bigger questions and unlock discoveries that were previously out of reach," said Serge Saxonov, CEO of 10x Genomics. "Spatial biology and advanced AI is the future of precision medicine. We are proud to partner with A*STAR GIS to accelerate the development of new diagnostics and therapies."
About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X (Twitter), Facebook, Bluesky or YouTube.
About A*STAR Genome Institute of
The A*STAR Genome Institute of
Key research areas at A*STAR GIS include Precision Medicine & Population Genomics, Genome Informatics, Spatial & Single Cell Systems, Epigenetic & Epitranscriptomic Regulation, Genome Architecture & Design, and Sequencing Platforms. The genomics infrastructure at A*STAR GIS is also utilised to train new scientific talent, to function as a bridge for academic and industrial research, and to explore scientific questions of high impact.
For more information about A*STAR GIS, please visit www.a-star.edu.sg/gis
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements included in this press release, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "see," "estimate," "predict," "potential," "would," "likely," "seek" or "continue" or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics' products and collaborations. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management. Actual outcomes and results could differ materially from these statements due to a number of factors and such statements should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release. 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in 10x Genomics' expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. The material risks and uncertainties that could affect 10x Genomics, Inc.'s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's most recently-filed 10-Q for the fiscal quarter ended March 31, 2025 and 10-K for the fiscal year ended December 31, 2024 and elsewhere in the documents 10x Genomics, Inc. files with the Securities and Exchange Commission from time to time.
Disclosure Information
10x Genomics uses filings with the Securities and Exchange Commission, its website (https://www.10xgenomics.com/), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/10x-genomics-and-astar-genome-institute-of-singapore-launch-tishumap-study-to-advance-ai-driven-drug-target-discovery-302507388.html
SOURCE 10x Genomics, Inc.
FAQ
What is the TISHUMAP study announced by 10x Genomics (TXG)?
How many tissue samples will be analyzed in the TXG TISHUMAP study?
What technology will 10x Genomics use in the TISHUMAP study?
What are the goals of the 10x Genomics TISHUMAP collaboration?
How will the TXG Xenium platform contribute to the TISHUMAP study?
